 CAMBRIDGE, Mass., Sept. 01, 2021 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced that the Companys executive management team will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9-13, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 14, 2021. 